Your Health, We Care
Axitinib is a tyrosine kinase inhibitor primarily used for the treatment of renal cell carcinoma (RCC). It is an oral drug that acts on multiple targets such as the vascular endothelial growth factor receptor (VEGFR) to inhibit the growth of tumor cells by blocking tumor angiogenesis and metastasis pathways.
Axitinib was first approved by the FDA in January 2012 and approved by the CFDA in April 2015.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
